GlassScriptPhysician profile
Kadilee Adams
NPI 1073140612
$3,316.29
in general payments reported to CMS, 2019-2025
20 companies · $851 in 2025
The $851 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $222 · 2023: $919 · 2024: $1,325 · 2025: $851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,959 · Education: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,958.94 |
| Education | $135.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $610.80 | 2023-2025 | Dragonfly Opstar, Cardiomems, Ensite |
| Medtronic, INC. | $493.24 | 2024-2025 | Symplicity G3, Corevalve Evolut R, Cobalt Dr Mri Surescan |
| E.R. Squibb & Sons, L.L.C. | $472.31 | 2022-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $392.58 | 2024-2025 | |
| Abiomed | $254.22 | 2023-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $239.40 | 2023-2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $136.79 | 2023-2025 | |
| Abbvie INC. | $124.98 | 2025 | |
| Novo Nordisk INC | $124.26 | 2024 | Wegovy |
| United Therapeutics Corporation | $104.93 | 2024 | Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.32 | 2024 | Ofev |
| Angiodynamics, INC. | $58.39 | 2024-2025 | Alphavac |
| Teleflex LLC | $44.58 | 2023-2025 | Trapliner, Bandit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.54 | 2023 | Xifaxan |
| Alnylam Pharmaceuticals INC. | $26.52 | 2025 | Onpattro |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $23.48 | 2023 | Imfinzi |
| Janssen Pharmaceuticals, INC | $22.02 | 2023 | Xarelto |
| Bioxcel Therapeutics, INC. | $21.62 | 2023 | Igalmi |
| Cardiva Medical, INC. | $20.49 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Fisher & Paykel Healthcare INC | $17.82 | 2023 | Fisher & Paykel Healthcare |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kadilee Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.